FDA Approval: Maintenance Lurbinectedin for SCLC

In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recent FDA approval of maintenance lurbinectedin plus atezolizumab for extensive stage small cell lung cancer, based on the phase III IMforte trial. Dr. Hossein Borghaei joins the podcast to explain the results and offer perspective on the impact of maintenance therapy for SCLC.